Caution: This product is not recommended for use during pregnancy or breastfeeding
Researched applications In the published preclinical and clinical literature the effects of Cagrilintide are documented in the following areas: Obesity (stand-alone) , Phase 2 data (Lau 2021, 10.8 % at 4.5 mg) Obesity + Semaglutide (CagriSema) , Phase 3 REDEFINE 1 (25.3 %) T2DM + obesity , Phase 3 REDEFINE 2 Cardiovascular prevention , Phase 3 REDEFINE 3 (n ~ 7000) MASLD/MASH , exploratory in Phase 2 Type 2 diabetes (monotherapy) , preclinical data Prediabetes , exploratory plans Science & studies 4.1 Key publications Lau D.C.W., Erichsen L., Francisco A.M., et al
LL-37 (5mg) LL-37 Peptide 5mg (Lyophilized Peptide in 3ml Vial) For Research Use Only LL-37 is a human antimicrobial peptide derived from the cathelicidin family, extensively studied for its roles in innate immunity, antimicrobial defense, wound healing, and inflammation regulation
Life on Vancouver Island comes with some perks
In-Vitro Pharmacology and Selectivity Biochemical profiling places 5-Amino-1MQ potency for research NNMT in the low-micromolar IC range under standardized assay conditions, with cell-based EC values in the low micromolar range for lowering 1-MNA and suppressing lipogenesis
